JP2024532129A5 - - Google Patents

Info

Publication number
JP2024532129A5
JP2024532129A5 JP2024509031A JP2024509031A JP2024532129A5 JP 2024532129 A5 JP2024532129 A5 JP 2024532129A5 JP 2024509031 A JP2024509031 A JP 2024509031A JP 2024509031 A JP2024509031 A JP 2024509031A JP 2024532129 A5 JP2024532129 A5 JP 2024532129A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
therapeutically effective
subject
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024509031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532129A (ja
JP7887475B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/040747 external-priority patent/WO2023023245A1/en
Publication of JP2024532129A publication Critical patent/JP2024532129A/ja
Publication of JP2024532129A5 publication Critical patent/JP2024532129A5/ja
Application granted granted Critical
Publication of JP7887475B2 publication Critical patent/JP7887475B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024509031A 2021-08-19 2022-08-18 Ｐｃｓｋ９活性に関連する状態を治療するための化合物 Active JP7887475B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163234973P 2021-08-19 2021-08-19
US63/234,973 2021-08-19
US202163251972P 2021-10-04 2021-10-04
US63/251,972 2021-10-04
US202163263095P 2021-10-27 2021-10-27
US63/263,095 2021-10-27
US202263311622P 2022-02-18 2022-02-18
US63/311,622 2022-02-18
US202263371685P 2022-08-17 2022-08-17
US63/371,685 2022-08-17
PCT/US2022/040747 WO2023023245A1 (en) 2021-08-19 2022-08-18 Compounds for treating conditions related to pcsk9 activity

Publications (3)

Publication Number Publication Date
JP2024532129A JP2024532129A (ja) 2024-09-05
JP2024532129A5 true JP2024532129A5 (cg-RX-API-DMAC10.html) 2025-12-25
JP7887475B2 JP7887475B2 (ja) 2026-07-09

Family

ID=83319263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024509031A Active JP7887475B2 (ja) 2021-08-19 2022-08-18 Ｐｃｓｋ９活性に関連する状態を治療するための化合物

Country Status (9)

Country Link
US (1) US20240238367A1 (cg-RX-API-DMAC10.html)
EP (1) EP4387645A1 (cg-RX-API-DMAC10.html)
JP (1) JP7887475B2 (cg-RX-API-DMAC10.html)
KR (1) KR20240050369A (cg-RX-API-DMAC10.html)
AU (1) AU2022330007A1 (cg-RX-API-DMAC10.html)
CA (1) CA3228604A1 (cg-RX-API-DMAC10.html)
IL (1) IL310851A (cg-RX-API-DMAC10.html)
MX (1) MX2024002146A (cg-RX-API-DMAC10.html)
WO (1) WO2023023245A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025042927A2 (en) * 2023-08-24 2025-02-27 Merck Sharp & Dohme Llc Sustained-release formulations for poorly permeable cyclic peptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
CZ297264B6 (cs) 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
CA2415742A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
CA2495943C (en) 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2004019869A2 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
CA2512879A1 (en) 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
EP2174343A1 (en) 2007-06-28 2010-04-14 Semiconductor Energy Laboratory Co, Ltd. Manufacturing method of semiconductor device
US20100179173A1 (en) 2007-06-28 2010-07-15 Daniel Guay Substituted fused pyrimidines as antagonists of gpr105 activity
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
KR20250161677A (ko) 2018-06-21 2025-11-17 머크 샤프 앤드 돔 엘엘씨 Pcsk9 길항제 화합물
EP4021919A1 (en) * 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds

Similar Documents

Publication Publication Date Title
RU2441655C2 (ru) Агонисты каппа-опиоидов для лечения синдрома раздраженного кишечника с преобладанием диареи и перемежающегося синдрома раздраженного кишечника
US20090297598A1 (en) Therapeutic combination
US20240189311A1 (en) Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia
EA032515B1 (ru) Лечение или профилактика сердечно-сосудистых явлений с использованием колхицина
BRPI1007945B1 (pt) Formulação farmacêutica de liberação controlada de nitazoxamida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral
CN102056603A (zh) 决奈达隆用于预防持续性心房纤颤
JP6068765B2 (ja) 薬学的複合製剤
JP2007302657A (ja) 痙症の兆候および症候の緩和方法
JP2013529654A (ja) レボカルニチン及びドベシレートを含む医薬組成物
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
WO2025059594A1 (en) METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
JP2024539476A5 (cg-RX-API-DMAC10.html)
JP7827696B2 (ja) トリフェニルカルシリティック化合物の製剤
JP2025510311A5 (cg-RX-API-DMAC10.html)
JP2021066751A (ja) 経口用医薬組成物
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
EP2977048A1 (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
EP4185291B1 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
US9675552B2 (en) Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
EP2727595B1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
US20080145422A1 (en) Galantamine tablet formulation
US8685374B2 (en) EDTA containing compositions and uses thereof
RU2024106935A (ru) Соединения для лечения состояний, связанных с pcsk9-активностью
US20210052608A1 (en) Methods of treating bacterial infections with minocycline
EP3582786A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury